Page last updated: 2024-08-22
trolamine salicylate and Neointima
trolamine salicylate has been researched along with Neointima in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ahmet, I; Browe, D; Cruschwitz, S; Kim, JM; Lakatta, EG; Lee, YC; Li, G; Lin, L; Morrell, CH; Pang, J; Park, S; Petrashevskaya, N; Riebe, RA; Tae, HJ; Talan, MI; Tomiya, N; Wei, W; Xiao, RP; Zhang, Y | 1 |
Other Studies
1 other study(ies) available for trolamine salicylate and Neointima
| Article | Year |
|---|---|
The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.
Topics: Animals; Arthritis; Biomarkers; Carotid Arteries; Cell Movement; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Enzyme Activation; Glycosylation; Humans; Ligands; Male; Muscle, Smooth, Vascular; Neointima; NF-kappa B; Rats; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Recombinant Proteins; Sf9 Cells | 2013 |